The use of tocilizumab in severe glucocorticoid-resistant endocrine ophthalmopathy with optic neuropathy in clinical practice
Authors:
- N. Y. SviridenkoNSN. Y. Sviridenko
- E. V. AnanichevaEAE. V. Ananicheva
- V. M. GershevichVGV. M. Gershevich
- Y. O. GrushaYGY. O. Grusha
- K. A. ChepilevKCK. A. Chepilev
- A. V. SurovASA. V. Surov
- V. V. YurgelVYV. V. Yurgel
- K. S. ShchukinKSK. S. Shchukin
- E. G. BessmertnayaEBE. G. Bessmertnaya
- O. A. BilevichOBO. A. Bilevich
Open Access
- 18 January 2026
- journal article
- case report
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 71 (6) , 31-39
Abstract
Thyroid eye disease (TED) is an autoimmune pathology of the orbital tissues associated with autoimmune thyroid disease, most commonly occurring with Graves’ disease. The clinical presentation of TED is extremely diverse, ranging from mild orbital involvement to potentially vision-threatening optical neuropathy. Early diagnosis of the active phase of TED is crucial, as immunosuppressive therapy is effective only during this phase, while treatment for patients in the inactive phase consists only of rehabilitative surgery. High-dose intravenous glucocorticoids are the first-line treatment for patients with moderate to severe active TED. Glucocorticoids are widely used due to their anti-inflammatory and immunosuppressive properties, but about 20–30% of patients remain resistant to glucocorticoid treatment. One promising direction in the treatment of glucocorticoid-resistant TED is the use of monoclonal antibodies targeting specific antigen epitopes. We present a clinical case of tocilizumab treatment in severe glucocorticoid-resistant TED complicated by optic neuropathy.Keywords
This publication has 18 references indexed in Scilit:
- Tocilizumab use for optic nerve compression in thyroid eye disease: a prospective longitudinal cohortInternational Ophthalmology, 2024
- Efficiency and Safety of Tocilizumab for the Treatment of Thyroid Eye Disease: A Systematic ReviewOphthalmic Plastic & Reconstructive Surgery, 2024
- Dysthyroid optic neuropathy: emerging treatment strategiesJournal of Endocrinological Investigation, 2023
- Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and the European Thyroid AssociationThyroid®, 2022
- Long‐term outcomes in corticosteroid‐refractory Graves' orbitopathy treated with tocilizumabClinical Endocrinology, 2021
- Dysthyroid optic neuropathy: evaluation and managementJournal of Endocrinological Investigation, 2020
- Graves' disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapyBest Practice & Research Clinical Endocrinology & Metabolism, 2020
- Current Understanding of the Progression and Management of Thyroid Associated Orbitopathy: A Systematic ReviewOphthalmology and Therapy, 2019
- Tocilizumab for the Management of Corticosteroid-Resistant Mild to Severe Graves’ Ophthalmopathy, a Report of Three CasesOcular Immunology and Inflammation, 2018
- Tocilizumab as first treatment option in optic neuropathy secondary to Graves’ orbitopathyOrbit, 2018